-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is a neurodegenerative disease that mainly occurs in the elderly.
The most basic and often earliest clinical manifestation of AD is selective memory impairment, but there are exceptions.
The most basic and often earliest clinical manifestation of AD is selective memory impairment, but there are exceptions.
AD is usually seen in the elderly, rarely onset before the age of 60.
The incidence and prevalence of AD increase exponentially with age, and its prevalence will basically double every 5 years after the age of 65.
Apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic AD.
Schematic diagram of APOE's involvement in AD
Schematic diagram of APOE's involvement in ADIn order to describe the age-related clinical heterogeneity in AD and determine whether it is altered by APOE genotype or accompanying non-AD pathology, scholars from the United States conducted a retrospective cohort study and analyzed 1750 sporadic and pathologically confirmed Data on severe AD patients.
The results showed that in the cases of APOE ε4, the bimodal distribution of age of onset frequency showed the best separation at 63 years of age.
EOAD patients are more likely than LOAD patients to have non-cognitive behavior or motor symptoms or non-memory cognitive impairment, and have more executive dysfunction, but have less language impairment in objective cognitive tests.
EOAD patients are more likely than LOAD patients to have non-cognitive behavior or motor symptoms or non-memory cognitive impairment, and have more executive dysfunction, but have less language impairment in objective cognitive tests.
The relationship between APOE site and AD
The relationship between APOE site and ADAlthough they are more likely to be pure AD patients without vascular or other non-AD neurodegeneration, EOAD patients are more likely to receive a non-AD clinical diagnosis (misdiagnosis) than LOAD patients .
Vascular diagnosis
It can be seen that early-onset sporadic AD and atypical, non-memory-based clinical manifestations are more likely, especially in the absence of the APOE ε4 allele, which may be the main reason for misdiagnosis .
Thus, early-onset sporadic AD and atypical, more likely non-memory-based clinical manifestations, especially in the absence of APOE ε4 allele, the main reason for this may lead to misdiagnosis result It can be seen that early-onset sporadic AD and atypical, non-memory-based clinical manifestations are more likely, especially in the absence of APOE ε4 alleles, which may lead to the main reason for misdiagnosis
references:
Smirnov DS, et al.
neurology.
org/content/96/18/e2272.
abstract" target="_blank" rel="noopener">Age-of-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
Leave a message here
